• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

别嘌醇对非细菌性前列腺炎的改善作用:一项平行双盲对照研究。

Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double-blind controlled study.

作者信息

Persson B E, Ronquist G, Ekblom M

机构信息

Department of Urology, University Hospital, Uppsala, Sweden.

出版信息

J Urol. 1996 Mar;155(3):961-4.

PMID:8583618
Abstract

PURPOSE

Nonbacterial prostatitis is a common problem in young men. It is a disease that is often recurrent and each episode lasts for several months. Different causative mechanisms of the disease have been discussed, including identified and unidentified microorganisms, stone formation and psychological factors. We have demonstrated in a previous study that urinary reflux (as shown by a high creatinine concentration in prostatic fluid) occurs to a varying extent into the prostatic ducts, and this reflux has been related to prostatic pain and urate concentration in expressed prostatic secretion.

MATERIALS AND METHODS

We performed a paralled double-blind controlled study of the objective and subjective effects of allopurinol on patients with nonbacterial prostatitis. Twenty patients received placebo, 18 received 300 mg. allopurinol daily and 16 received 600 mg allopurinol daily for 240 days. All patients began medication at the same time regardless of whether the disease was in an active state. No side effects were noted in the treatment groups.

RESULTS

Significant effects were noted on the concentrations of serum urate, urine urate, expressed prostatic secretion urate, expressed prostatic secretion xanthine and subjective discomfort.

CONCLUSIONS

Allopurinol has a significant, positive effect on nonbacterial prostatitis. It is safe and worthy of trial for all at least a 3-month period at each episode to relieve the symptoms of nonbacterial prostatitis.

摘要

目的

非细菌性前列腺炎是年轻男性的常见问题。这是一种常复发的疾病,每次发作持续数月。该病不同的致病机制已被探讨,包括已识别和未识别的微生物、结石形成及心理因素。我们在之前的一项研究中表明,尿液反流(如前列腺液中肌酐浓度升高所示)在不同程度上会发生至前列腺导管,且这种反流与前列腺疼痛及前列腺液中尿酸盐浓度有关。

材料与方法

我们对别嘌醇治疗非细菌性前列腺炎患者的客观和主观效果进行了一项平行双盲对照研究。20名患者接受安慰剂,18名患者每日服用300毫克别嘌醇,16名患者每日服用600毫克别嘌醇,为期240天。所有患者无论疾病是否处于活动期均同时开始用药。治疗组未观察到副作用。

结果

在血清尿酸盐、尿尿酸盐、前列腺液尿酸盐、前列腺液黄嘌呤浓度及主观不适方面均观察到显著效果。

结论

别嘌醇对非细菌性前列腺炎有显著的积极作用。它安全,每次发作至少试用3个月以缓解非细菌性前列腺炎症状是值得的。

相似文献

1
Ameliorative effect of allopurinol on nonbacterial prostatitis: a parallel double-blind controlled study.别嘌醇对非细菌性前列腺炎的改善作用:一项平行双盲对照研究。
J Urol. 1996 Mar;155(3):961-4.
2
Allopurinol treatment results in elevated prostate-specific antigen levels in prostatic fluid and serum of patients with non-bacterial prostatitis.别嘌醇治疗会导致非细菌性前列腺炎患者前列腺液和血清中前列腺特异性抗原水平升高。
Eur Urol. 1996;29(1):111-4. doi: 10.1159/000473728.
3
Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion.
J Urol. 1996 Mar;155(3):958-60.
4
Allopurinol for chronic prostatitis.
Cochrane Database Syst Rev. 2002(4):CD001041. doi: 10.1002/14651858.CD001041.
5
Effect of allopurinol in chronic nonbacterial prostatitis: a double blind randomized clinical trial.别嘌醇治疗慢性非细菌性前列腺炎的疗效:一项双盲随机临床试验。
Int Braz J Urol. 2006 Mar-Apr;32(2):181-6. doi: 10.1590/s1677-55382006000200008.
6
Allopurinol for chronic prostatitis.别嘌醇用于慢性前列腺炎。
Cochrane Database Syst Rev. 2000;2002(2):CD001041. doi: 10.1002/14651858.CD001041.
7
Effects of pollen extract preparation Prostat/Poltit on lower urinary tract symptoms in patients with chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized, double-blind, placebo-controlled study.花粉提取物制剂Prostat/Poltit对慢性非细菌性前列腺炎/慢性盆腔疼痛综合征患者下尿路症状的影响:一项随机、双盲、安慰剂对照研究。
Urology. 2006 Jan;67(1):60-3. doi: 10.1016/j.urology.2005.07.035.
8
[A clinical study of prostat combined with an antibiotic for chronic nonbacterial prostatitis].前列安栓联合抗生素治疗慢性非细菌性前列腺炎的临床研究
Zhonghua Nan Ke Xue. 2006 Sep;12(9):807-10.
9
Seminal fluid findings in men with nonbacterial prostatitis and prostatodynia.非细菌性前列腺炎和前列腺痛男性的精液检查结果
J Androl. 1996 May-Jun;17(3):310-8.
10
A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis.一项评估罗非昔布治疗慢性非细菌性前列腺炎的安全性和有效性的随机、安慰剂对照、多中心研究。
J Urol. 2003 Apr;169(4):1401-5. doi: 10.1097/01.ju.0000054983.45096.16.

引用本文的文献

1
Testing for Causal Association between Serum Urate, Gout, and Prostatic Cancer in European Males.欧洲男性血清尿酸、痛风与前列腺癌之间因果关联的检测
medRxiv. 2025 May 11:2025.05.09.25327351. doi: 10.1101/2025.05.09.25327351.
2
Systemic Urate Deposition: An Unrecognized Complication of Gout?全身尿酸沉积:痛风一种未被认识的并发症?
J Clin Med. 2020 Oct 3;9(10):3204. doi: 10.3390/jcm9103204.
3
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome.治疗慢性前列腺炎/慢性盆腔疼痛综合征的药物干预措施。
Cochrane Database Syst Rev. 2019 Oct 6;10(10):CD012552. doi: 10.1002/14651858.CD012552.pub2.
4
Chronic bacterial prostatitis and chronic pelvic pain syndrome.慢性细菌性前列腺炎和慢性盆腔疼痛综合征。
BMJ Clin Evid. 2015 Aug 27;2015:1802.
5
Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study.心脏和前列腺组织中双折射晶体的患病率:一项观察性研究
BMJ Open. 2014 Jul 16;4(7):e005308. doi: 10.1136/bmjopen-2014-005308.
6
Tamsulosin Monotherapy versus Combination Therapy with Antibiotics or Anti-Inflammatory Agents in the Treatment of Chronic Pelvic Pain Syndrome.坦索罗辛单药治疗与抗生素或抗炎药联合治疗慢性盆腔疼痛综合征的疗效比较。
Int Neurourol J. 2011 Jun;15(2):92-6. doi: 10.5213/inj.2011.15.2.92. Epub 2011 Jun 30.
7
Chronic prostatitis.慢性前列腺炎
BMJ Clin Evid. 2011 Jul 4;2011:1802.
8
Chronic prostatitis.慢性前列腺炎
BMJ Clin Evid. 2008 May 22;2008:1802.
9
Chronic prostatitis.慢性前列腺炎
West J Med. 2000 Feb;172(2):98-101. doi: 10.1136/ewjm.172.2.98.
10
[Psychosomatic aspects of the chronic pelvic pain syndrome].
Urologe A. 2004 Mar;43(3):254-60. doi: 10.1007/s00120-003-0511-4.